Evidence map›Paper›PMID 35454123›Full record

ArticleBiomolecules2022

Cytokine Profile and Anti-Inflammatory Activity of a Standardized Conditioned Medium Obtained by Coculture of Monocytes and Mesenchymal Stromal Cells (PRS CK STORM).

Juan Pedro Lapuente, Alejandro Blázquez-Martínez, Joaquín Marco-Brualla, Gonzalo Gómez, Paula Desportes, Jara Sanz, Pablo Fernández, Mario García-Gil, Fernando Bermejo, Juan V San Martín and 7 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Biomolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06684379 (Double-blind, Randomized, Placebo-controlled, Pilot Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Two Doses of a Conditioned Medium From a Co-culture of M2-macrophages and Fat-derived Mesenchymal Cells), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06684379 phase1 / phase2recruitingnot on this mapstarted 2024, after this paper: background citation

Double-blind, Randomized, Placebo-controlled, Pilot Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Two Doses of a Conditioned Medium From a Co-culture of M2-macrophages and Fat-derived Mesenchymal Cells (PRS CK STORM) in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)

TypeinterventionalSponsorPEACHES BIOTECHRan2024 to 2026Enrolled50ConditionsSARS-CoV-2, Influenza, Human, Respiratory Syncytial Virus Infections, Respiratory Distress SyndromeArmsPlacebo comparator, PRS CK STORM
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Juan Pedro LapuenteR4T Molecular and Cell Biology Research Laboratories, Fuenlabrada Hospital, 28942 Madrid, Spain.ORCID 0000-0003-3054-4589
Alejandro Blázquez-MartínezR4T Molecular and Cell Biology Research Laboratories, Fuenlabrada Hospital, 28942 Madrid, Spain.ORCID 0000-0002-6522-7738
Joaquín Marco-BruallaGroup Immunity, Cancer and Stem Cells, Faculty of Sciences, University of Zaragoza, 50009 Zaragoza, Spain.ORCID 0000-0002-1710-4821
Gonzalo GómezR4T Molecular and Cell Biology Research Laboratories, Fuenlabrada Hospital, 28942 Madrid, Spain.
Paula DesportesGMP Facility, Peaches Biotech, 28050 Madrid, Spain.
Jara SanzGMP Facility, Peaches Biotech, 28050 Madrid, Spain.
Pablo FernándezR4T Molecular and Cell Biology Research Laboratories, Fuenlabrada Hospital, 28942 Madrid, Spain.
Mario García-GilPharmacy Department, Fuenlabrada Hospital, 28942 Madrid, Spain.
Fernando BermejoDigestive Department, Fuenlabrada Hospital, 28942 Madrid, Spain.
Juan V San MartínInternal Medicine Department, Fuenlabrada Hospital, 28942 Madrid, Spain.ORCID 0000-0003-4457-5124
Alicia AlgabaClinical Assay Department, Fuelabrada Hospital, 28942 Madrid, Spain.
Juan Carlos De GregorioR4T Molecular and Cell Biology Research Laboratories, Fuenlabrada Hospital, 28942 Madrid, Spain.
Daniel LapuenteR4T Molecular and Cell Biology Research Laboratories, Fuenlabrada Hospital, 28942 Madrid, Spain.
Almudena De GregorioR4T Molecular and Cell Biology Research Laboratories, Fuenlabrada Hospital, 28942 Madrid, Spain.
Belén LapuenteR4T Molecular and Cell Biology Research Laboratories, Fuenlabrada Hospital, 28942 Madrid, Spain.
María de la Viñas AndrésR4T Molecular and Cell Biology Research Laboratories, Fuenlabrada Hospital, 28942 Madrid, Spain.
Alberto AnelGroup Immunity, Cancer and Stem Cells, Faculty of Sciences, University of Zaragoza, 50009 Zaragoza, Spain.ORCID 0000-0002-5175-8394
Hospital Universitario de Fuenlabrada · ESUniversidad de Zaragoza · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intercellular communication between monocytes/macrophages and cells involved in tissue regeneration, such as mesenchymal stromal cells (MSCs) and primary tissue cells, is essential for tissue regeneration and recovery of homeostasis. Typically, in the final phase of the inflammation-resolving process, this intercellular communication drives an anti-inflammatory immunomodulatory response. To obtain a safe and effective treatment to counteract the cytokine storm associated with a disproportionate immune response to severe infections, including that associated with COVID-19, by means of naturally balanced immunomodulation, our group has standardized the production under GMP-like conditions of a secretome by coculture of macrophages and MSCs. To characterize this proteome, we determined the expression of molecules related to cellular immune response and tissue regeneration, as well as its possible toxicity and anti-inflammatory potency. The results show a specific molecular pattern of interaction between the two cell types studied, with an anti-inflammatory and regenerative profile. In addition, the secretome is not toxic by itself on human PBMC or on THP-1 monocytes and prevents lipopolysaccharide (LPS)-induced growth effects on those cell types. Finally, PRS CK STORM prevents LPS-induced TNF-A and IL-1Β secretion from PBMC and from THP-1 cells at the same level as hydrocortisone, demonstrating its anti-inflammatory potency.

Indexed as

COVID-19Mesenchymal Stem CellsAnti-Inflammatory AgentsCoculture TechniquesCulture Media, ConditionedHumansLeukocytes, MononuclearLipopolysaccharidesMonocytesAnti-Inflammatory AgentsCulture Media, ConditionedLipopolysaccharidescoculturecrosstalkinflammationmonocyteMSCsecretome

Identifiers

PMID35454123
PMCPMC9029939
OpenAlexW4220850504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.